Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study | Zendy

Maximilian Posch | Zendy; Niklas Walther | Zendy; Ele Ferrannini | Zendy; David R. Powell | Zendy; Phillip Banks | Zendy; Suman Wason | Zendy; Raphael Dahmen | Zendy

Open Access

Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study

Author(s) -

Maximilian Posch,

Niklas Walther,

Ele Ferrannini,

David R. Powell,

Phillip Banks,

Suman Wason,

Raphael Dahmen

Publication year - 2022

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc21-2166

Subject(s) - medicine , empagliflozin , diabetes mellitus , type 2 diabetes , randomized controlled trial , double blind , gastroenterology , endocrinology , pathology , alternative medicine , placebo

Inhibiting sodium-glucose cotransporters (SGLTs) improves glycemic and cardiovascular outcomes in patients with type 2 diabetes (T2D). We investigated the differential impact of selective SGLT2 inhibition and dual inhibition of SGLT1 and SGLT2 on multiple parameters.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research